Allogeneic stem cell transplantation as treatment for heavily treated, refractory acute graft-versus-host disease after HLA-mismatched stem cell transplantation
- 31 August 2011
- journal article
- Published by Elsevier BV in Experimental Hematology
- Vol. 39 (8), 880-890
- https://doi.org/10.1016/j.exphem.2011.05.007
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- Recovery from established graft-vs-host disease achieved by bone marrow transplantation from a third-party allogeneic donorExperimental Hematology, 2008
- Unmanipulated HLA 2-3 antigen–mismatched (haploidentical) bone marrow transplantation using only pharmacological GVHD prophylaxisExperimental Hematology, 2008
- How I treat refractory acute GVHDBlood, 2007
- National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. Diagnosis and Staging Working Group ReportTransplantation and Cellular Therapy, 2005
- Pentostatin in Steroid-Refractory Acute Graft-Versus-Host DiseaseJournal of Clinical Oncology, 2005
- Autologous/syngeneic stem cell transplantation to treat refractory GvHDBone Marrow Transplantation, 2004
- Association of Foxp3 regulatory gene expression with graft-versus-host diseaseBlood, 2004
- Intestinal thrombotic microangiopathy after allogeneic bone marrow transplantation: a clinical imitator of acute enteric graft-versus-host diseaseBone Marrow Transplantation, 2004
- Successful engraftment of HLA-haploidentical related transplants using nonmyeloablative conditioning with fludarabine, busulfan and anti-T-lymphocyte globulinLeukemia, 2003
- Prevention of Graft Versus Host Disease by Inactivation of Host Antigen-Presenting CellsScience, 1999